By Fineline Cube 
Genscript Biotech Corporation (HKG: 1548) announced that it proposes to spin off its indirect non-wholly-owned subsidiary, Probio Technology Limited (“ProBio”), and separately list its shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX). The move would unlock a standalone listing for GenScript’s Biologics and Advanced Therapy CDMO business, following the Listing Committee’s confirmation on 14 August 2026 that the company may proceed with the proposed spin-off under Practice Note 15 of the Listing Rules.
Transaction Overview
| Item | Detail |
|---|---|
| Parent Company | Genscript Biotech Corporation (HKG: 1548) |
| Spin-Off Entity | Probio Technology Limited (“ProBio”), an indirect non-wholly-owned subsidiary |
| Listing Venue | Main Board of The Stock Exchange of Hong Kong Limited (HKEX) |
| Regulatory Basis | Application submitted in compliance with Practice Note 15 of the Listing Rules |
| Key Milestone | 14 Aug 2026 – Listing Committee confirmed GenScript may proceed with the Proposed Spin-off |
| Next Steps | Preparation and submission of the listing application for ProBio on the HKEX Main Board |
Business Profile: ProBio
- Core Business: Operates GenScript’s Biologics and Advanced Therapy Contract Research, Development, and Manufacturing Organization (CDMO) services
- Service Scope: Integrated CRDMO platform spanning biologics and advanced therapy development and manufacturing
- Strategic Rationale: A standalone listing is designed to sharpen the CDMO business’s market profile, broaden its financing channels, and align management incentives with operational performance
- Relationship to Parent: ProBio is an indirect, non-wholly-owned subsidiary, and would remain within the GenScript group structure post-listing
Regulatory & Procedural Status
- GenScript has submitted the spin-off application to the Stock Exchange in accordance with Practice Note 15 of the Listing Rules, the framework governing the separate listing of subsidiaries
- On 14 August 2026, the Listing Committee confirmed that the Company may proceed with the Proposed Spin-off
- The announcement of 04 September 2026 formalizes the board’s proposal for the separate listing of ProBio shares
Market Impact & Outlook
- Value unlocking: A standalone HKEX listing could give the market direct visibility into the CDMO business, potentially supporting a valuation independent of GenScript’s diversified group structure
- Capital access: Independent listing status would provide ProBio with its own equity financing platform to fund capacity expansion in biologics and advanced therapy manufacturing
- Sector positioning: Separation underscores the strategic importance of the CDMO segment amid growing global demand for biologics and cell & gene therapy development services
- Governance signal: Compliance with Practice Note 15 and Listing Committee clearance demonstrate a structured, regulator-aligned path toward execution, though completion remains subject to further approvals and listing process milestones
Forward‑Looking Statements: This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding the proposed spin-off, listing timeline and strategic benefits are forward-looking and subject to risks and uncertainties, including regulatory approvals, market conditions and the outcome of the listing process. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.-Fineline Info & Tech